Prescribing Information (PI) for COMIRNATY® LP.8.1▼ (mRNA encoding LP.8.1) COVID-19 mRNA vaccine, COMIRNATY® JN.1▼ (bretovameran) COVID-19 mRNA vaccine and COMIRNATY® KP.2▼(cemivameran) COVID-19 mRNA vaccine

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
 
Healthcare professionals are asked to report any suspected adverse reactions via the Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
 
Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.
 
Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.